Gainers

• Virax Biolabs Group (NASDAQ:VRAX) stock rose 34.8% to $0.23 during Friday's after-market session. The market value of their outstanding shares is at $1.0 million.
• Edesa Biotech (NASDAQ:EDSA) stock increased by 6.56% to $17.37. The market value of their outstanding shares is at $145.5 million.
• Inhibrx Biosciences (NASDAQ:INBX) shares increased by 6.36% to $142.9. The company's market cap stands at $1.8 billion.
• Aethlon Medical (NASDAQ:AEMD) shares rose 6.19% to $2.39. The market value of their outstanding shares is at $3.6 million.
• InflaRx (NASDAQ:IFRX) shares rose 5.81% to $2.73. The market value of their outstanding shares is at $191.5 million. As per the press release, Q1 earnings came out yesterday.
• BGM Group (NASDAQ:BGM) shares moved upwards by 5.8% to $0.31. The market value of their outstanding shares is at $57.4 million.

Losers

• Pomdoctor (NASDAQ:POM) stock declined by 14.3% to $0.06 during Friday's after-market session. The company's market cap stands at $63.3 million.
• First Tracks (NASDAQ:TRAX) shares fell 13.46% to $16.91. The market value of their outstanding shares is at $619.2 million.
• Accuray (NASDAQ:ARAY) shares declined by 11.08% to $0.34. The company's market cap stands at $34.8 million. The company's, Q3 earnings came out 2 days ago.
• Quantum Cyber (NASDAQ:QUCY) stock declined by 8.65% to $0.33. The market value of their outstanding shares is at $4.6 million.
• iTonic Holdings (NASDAQ:ITOC) shares decreased by 8.17% to $0.29. The company's market cap stands at $5.7 million.
• Cytek Biosciences (NASDAQ:CTKB) stock decreased by 7.83% to $4.25. The market value of their outstanding shares is at $635.3 million. The company's, Q1 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.